<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
<title>Dr Xavier TD</title>
<link href="http://starc.stthomas.ac.in:8080/xmlui/xmlui/handle/123456789/369" rel="alternate"/>
<subtitle/>
<id>http://starc.stthomas.ac.in:8080/xmlui/xmlui/handle/123456789/369</id>
<updated>2026-04-09T08:57:49Z</updated>
<dc:date>2026-04-09T08:57:49Z</dc:date>
<entry>
<title>Adverse Drug Reactions (ADR) necessitating modification of multi-drug therapy (MDT) in Hansens disease: a retrospective study from Kerala, India</title>
<link href="http://starc.stthomas.ac.in:8080/xmlui/xmlui/handle/123456789/370" rel="alternate"/>
<author>
<name>Ambooken, Betsy</name>
</author>
<author>
<name>George, Sandhya</name>
</author>
<author>
<name>Azeez, Neema</name>
</author>
<author>
<name>Asokan, N</name>
</author>
<author>
<name>Xavier, TD</name>
</author>
<id>http://starc.stthomas.ac.in:8080/xmlui/xmlui/handle/123456789/370</id>
<updated>2025-01-15T06:07:25Z</updated>
<published>2017-06-01T00:00:00Z</published>
<summary type="text">Adverse Drug Reactions (ADR) necessitating modification of multi-drug therapy (MDT) in Hansens disease: a retrospective study from Kerala, India
Ambooken, Betsy; George, Sandhya; Azeez, Neema; Asokan, N; Xavier, TD
Objective:&#13;
To assess the frequency and type of adverse drug reactions (ADR) that necessitated modification of multi-drug therapy (MDT) in Hansen’s disease, with emphasis to find out the interval between initiation of MDT and the occurrence of ADR.&#13;
&#13;
Design:&#13;
A retrospective analysis of case records of patients diagnosed with Hansen’s disease (HD) and registered for MDT in a tertiary care institution between 2010 and 2015. Clinical details and laboratory data were collected using a proforma.&#13;
&#13;
Results:&#13;
One hundred and ninety-six patients were registered for treatment during the study period. We analysed 150 records that met the inclusion criteria. Thirty-six among them (24%) had ADR that needed modification of MDT. The most common ADR was haemolytic anemia (19 patients; 12.7%) followed by hepatitis (14 patients; 9.3%). The most serious ADR was agranulocytosis (three patients; 2%). Adverse effects were more common (72%) during the initial 2 months of MDT compared to later months. (P = 0.004).
</summary>
<dc:date>2017-06-01T00:00:00Z</dc:date>
</entry>
</feed>
